{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+sodium+chloride+solution&page=37",
    "query": {
      "intervention": "0.9% sodium chloride solution",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1016,
    "total_pages": 102,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+sodium+chloride+solution&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+sodium+chloride+solution&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T22:51:46.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04213274",
      "title": "Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schnitzler Syndrome",
        "Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)"
      ],
      "interventions": [
        {
          "name": "80 mg RPH-104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "R-Pharm Overseas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-05",
      "completion_date": "2024-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213274"
    },
    {
      "nct_id": "NCT04799249",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2021-05-14",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Clinton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04799249"
    },
    {
      "nct_id": "NCT01175018",
      "title": "Anakinra to Prevent Adverse Post-infarction Remodeling (2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myocardial Infarction",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-07",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-05-23",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01175018"
    },
    {
      "nct_id": "NCT00772343",
      "title": "Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diarrhea",
        "Clostridium Difficile Infection"
      ],
      "interventions": [
        {
          "name": "0.9% Normal Saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clostridium difficile toxoid vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clostridium difficile toxoid vaccine with adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 116,
      "start_date": "2009-02",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Marietta, Georgia • Worcester, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Butte",
          "state": "Montana"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772343"
    },
    {
      "nct_id": "NCT03411850",
      "title": "Sjogrens Syndrome Measured by Ultrasound",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjogren's Syndrome"
      ],
      "interventions": [
        {
          "name": "Orencia",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Arthritis & Rheumatism Associates, P.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-05",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 1,
      "location_summary": "Wheaton, Maryland",
      "locations": [
        {
          "city": "Wheaton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03411850"
    },
    {
      "nct_id": "NCT00912925",
      "title": "Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucopolysaccharidosis I",
        "Hurlers Syndrome",
        "Hurler-Scheie Syndrome"
      ],
      "interventions": [
        {
          "name": "rhIDU (recombinant human-Alpha-L-Iduronidase)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2000-12",
      "completion_date": "2001-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 2,
      "location_summary": "New York, New York • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912925"
    },
    {
      "nct_id": "NCT04350138",
      "title": "Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonococcal Infection"
      ],
      "interventions": [
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2606,
      "start_date": "2020-12-29",
      "completion_date": "2026-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04350138"
    },
    {
      "nct_id": "NCT05454410",
      "title": "Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Treatment-Resistant Depression"
      ],
      "interventions": [
        {
          "name": "MIJ821 Subcutaneous Injection 1 mg",
          "type": "DRUG"
        },
        {
          "name": "MIJ821 Subcutaneous Injection 4 mg",
          "type": "DRUG"
        },
        {
          "name": "MIJ821 Subcutaneous Injection 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Subcutaneous Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2023-03-13",
      "completion_date": "2023-11-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland Park",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05454410"
    },
    {
      "nct_id": "NCT03970213",
      "title": "Intravenous Tranexamic Acid During Rhytidectomy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bleeding",
        "Bruising Face",
        "Swelling Lips & Face"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid 100Mg/Ml Inj Vil 10Ml",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline 0.9% Infusion Solution Bag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glasgold Group Plastic Surgery",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-05-30",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2019-05-31",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970213"
    },
    {
      "nct_id": "NCT00316017",
      "title": "Hypertonic Resuscitation Following Traumatic Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Shock, Traumatic"
      ],
      "interventions": [
        {
          "name": "7.5% hypertonic saline/6% Dextran-70 (HSD)",
          "type": "DRUG"
        },
        {
          "name": "7.5% hypertonic saline (HS)",
          "type": "DRUG"
        },
        {
          "name": "0.9% normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 895,
      "start_date": "2006-05",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2011-03-01",
      "last_synced_at": "2026-10-16T22:51:46.639Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00316017"
    }
  ]
}